medsovetМедицинский СоветMeditsinskiy sovet = Medical Council2079-701X2658-5790REMEDIUM GROUP Ltd.10.21518/2079-701X-2016-19-71-73medsovet-1630Research ArticleГАСТРОЭНТЕРОЛОГИЯGASTROENTEROLOGYВОЗМОЖНОСТИ МНОГОЦЕЛЕВОЙ ТЕРАПИИ ФУНКЦИОНАЛЬНЫХ РАССТРОЙСТВ ЖЕЛУДОЧНО-КИШЕЧНОГО ТРАКТАPOSSIBILITIES OF MULTI-TARFGETED THERAPY OF FUNCTIONAL GASTROINTESTINAL TRACT DISTURBANCESСАСЕ. И.SADE. I.

д.м.н., профессор

MD, Prof.

УСПЕНСКИЙЮ. П.USPENSKYY. P.

д.м.н., профессор

MD, Prof.

Санкт-Петербургский государственный университет им. И.П. Павлова Санкт-Петербургский государственный педиатрический университетРоссияPavlov Saint-Petersburg State University Saint-Petersburg State Pediatric UniversityRussian FederationСанкт-Петербургский государственный университет им. И.П. ПавловаРоссияPavlov Saint-Petersburg State UniversityRussian Federation2016301220160197173Copyright © САС Е.И., УСПЕНСКИЙ Ю.П., 20162016САС Е.И., УСПЕНСКИЙ Ю.П.SAD E.I., USPENSKY Y.P.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-sovet.pro/jour/article/view/1630

В структуре заболеваний желудочно-кишечного тракта (ЖКТ) значительный сегмент представлен функциональной патологией. Эта достаточно большая и гетерогенная группа заболеваний объединяет самые различные по патогенезу нозологические формы (функциональная абдоминальная боль, функциональный запор, синдром раздраженного кишечника (СРК), функциональный метеоризм и т. д.), общность которых основана на их функциональной природе.

A considerable segment in the structure of gastrointestinal tracts diseases is represented by the functional pathology. This sufficiently large and heterogeneous group of diseases unites nosologic forms different by pathogenesis (functional abdominal pain, functional constipation, irritable bowel syndrome (IBS), functional flatulency etc.) different by pathogenesis, the similarity of which is based on their functional nature.

желудочно-кишечный трактфункциональные расстройствакомбинированные растительные препаратыgastrointestinal tractfunctional disturbancescombined herbal drugsReferencesБаранская Е.К. Синдром раздраженного кишечника: диагностика и лечение. Consilium medicum, 2000, 2(7).Баранская Е.К. Синдром раздраженного кишечника: диагностика и лечение. Consilium medicum, 2000, 2(7).Locke GR, III, Zinsmeister A, Talley NJ, Fett SL, Melton J. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc, 2000, 75: 907-912.Locke GR, III, Zinsmeister A, Talley NJ, Fett SL, Melton J. Familial association in adults with functional gastrointestinal disorders. Mayo Clin Proc, 2000, 75: 907-912.Баранская Е.К. Синдром раздраженного кишечника: диагностика и лечение. Consilium medicum, 2002, 4(9).Баранская Е.К. Синдром раздраженного кишечника: диагностика и лечение. Consilium medicum, 2002, 4(9).Costanza C, Longstreth G, Liu A. Chronic abdominal wall pain: clinical features, health care costs, and long-term outcome. Clin Gastroenterol Hepatol, 2004, 2: 395-399.Costanza C, Longstreth G, Liu A. Chronic abdominal wall pain: clinical features, health care costs, and long-term outcome. Clin Gastroenterol Hepatol, 2004, 2: 395-399.Маев И.В., Черемушкин С.В. Заболевания кишечника. Синдром раздраженного кишечника. Римские критерии III. Consilium medicum, 2007, 09(1).Маев И.В., Черемушкин С.В. Заболевания кишечника. Синдром раздраженного кишечника. Римские критерии III. Consilium medicum, 2007, 09(1).Sagami Y, Shimada Y, Tayama J, Nomura T, Satake M, Endo Y, et al. Effect of a corticotrophin-releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut, 2004, 53: 958-964.Sagami Y, Shimada Y, Tayama J, Nomura T, Satake M, Endo Y, et al. Effect of a corticotrophin-releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut, 2004, 53: 958-964.Galligan JJ, Vanner S. Basic and clinical pharmacology of new motility promoting agents 1. Neurogastroenterol Motil, 2005, 17: 643-653.Galligan JJ, Vanner S. Basic and clinical pharmacology of new motility promoting agents 1. Neurogastroenterol Motil, 2005, 17: 643-653.Keefer L, Sanders K, Sykes MA, Blanchard EB, Lackner JM, Krasner S. Towards a better understanding of anxiety in irritable bowel syndrome: a preliminary look at worry and intolerance of uncer tainty. J Cognitive Psychother, 2005, 19: 163-172.Keefer L, Sanders K, Sykes MA, Blanchard EB, Lackner JM, Krasner S. Towards a better understanding of anxiety in irritable bowel syndrome: a preliminary look at worry and intolerance of uncer tainty. J Cognitive Psychother, 2005, 19: 163-172.Kim HJ, Camilleri M, Carlson PJ, Cremonini F, Ferber I, Stephens D, et al. Association of distinct alpha(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut, 2004, 53: 829-837.Kim HJ, Camilleri M, Carlson PJ, Cremonini F, Ferber I, Stephens D, et al. Association of distinct alpha(2) adrenoceptor and serotonin transporter polymorphisms with constipation and somatic symptoms in functional gastrointestinal disorders. Gut, 2004, 53: 829-837.Longstreth GF, Drossman DA. Severe irritable bowel and functional abdominal pain syndromes: managing the patient and health care costs. Clin Gastroenterol Hepatol, 2005, 3: 397-400.Longstreth GF, Drossman DA. Severe irritable bowel and functional abdominal pain syndromes: managing the patient and health care costs. Clin Gastroenterol Hepatol, 2005, 3: 397-400.Whitehead WE, Delvaux M. Standardization of procedures for testing smooth muscle tone and sensory thresholds in the gastrointestinal tract. Dig Dis Sci, 1994, 42: 223-241.Whitehead WE, Delvaux M. Standardization of procedures for testing smooth muscle tone and sensory thresholds in the gastrointestinal tract. Dig Dis Sci, 1994, 42: 223-241.Yeo A, Boyd P, Lumsden S, Saunders T, Handley A, Stubbins M, et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut, 2004, 53: 1452-14.Yeo A, Boyd P, Lumsden S, Saunders T, Handley A, Stubbins M, et al. Association between a functional polymorphism in the serotonin transporter gene and diarrhoea predominant irritable bowel syndrome in women. Gut, 2004, 53: 1452-14.von Arnim U, Peitz U, Vinson B. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol, 2007, 102: 1268-75.von Arnim U, Peitz U, Vinson B. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol, 2007, 102: 1268-75.Buchert D. Wirksamkeit und Verträglichkeit von Iberogast bei Patienten mit gesicherter Non Ulcus Dyspepsie. Z Phytotherapie, 1994, 15(1): 45-6.Buchert D. Wirksamkeit und Verträglichkeit von Iberogast bei Patienten mit gesicherter Non Ulcus Dyspepsie. Z Phytotherapie, 1994, 15(1): 45-6.Madisch A, Melderis H, Mayr G. Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie. Z Gastroenterologie, 2001, 39: 1-8.Madisch A, Melderis H, Mayr G. Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie. Z Gastroenterologie, 2001, 39: 1-8.Braden B, Caspary W, Börner N. Clinical effects of STW 5 (Iberogast) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis. Neurogastroenterol Motil, 2009 21(6): 632-8.Braden B, Caspary W, Börner N. Clinical effects of STW 5 (Iberogast) are not based on acceleration of gastric emptying in patients with functional dyspepsia and gastroparesis. Neurogastroenterol Motil, 2009 21(6): 632-8.Rösch W, Vinson B, Sassin I. A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z Gastroenterol, 2002, 40(6): 401-8.Rösch W, Vinson B, Sassin I. A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z Gastroenterol, 2002, 40(6): 401-8.Madisch A, Holtmann G, Plein K. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther, 2004, 19(3): 271-9.Madisch A, Holtmann G, Plein K. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther, 2004, 19(3): 271-9.Klein-Galczinsky C, Sassin I. Anwendungsbeobachtung zur Wirksamkeit und Verträglichkeit von Iberogast® in der Therapie des Colon irritabile. Phytotherapie an der Schwelle zum neuen Jahrtausend, 1999, 125.Klein-Galczinsky C, Sassin I. Anwendungsbeobachtung zur Wirksamkeit und Verträglichkeit von Iberogast® in der Therapie des Colon irritabile. Phytotherapie an der Schwelle zum neuen Jahrtausend, 1999, 125.Wagner H. Multitarget therapy: the future of treatment for more than just functional dyspepsia. Phytomedicine, 2006, 13(Suppl. 5): 122-99.Wagner H. Multitarget therapy: the future of treatment for more than just functional dyspepsia. Phytomedicine, 2006, 13(Suppl. 5): 122-99.

The authors declare that there are no conflicts of interest present.